湖南南新制药股份有限公司关于公司独立董事离任的公告

Group 1 - The independent director Shen Yunqiao has submitted his resignation due to personal reasons, stepping down from multiple positions including independent director and committee roles [2][3] - Shen's resignation will result in a non-compliance with legal and regulatory requirements regarding the proportion of independent directors on the board and its committees [3] - The company will expedite the process of electing a new independent director to ensure compliance with relevant regulations [3] Group 2 - The company has approved a share repurchase plan, allowing for the buyback of shares using funds between RMB 10 million and RMB 20 million, with a maximum repurchase price of RMB 9.53 per share [7] - As of December 2025, the company has repurchased a total of 1,910,214 shares, representing 0.70% of the total share capital, with a total expenditure of RMB 16,138,029.08 [8] - The repurchase activities are in accordance with legal regulations and the company's repurchase plan [9]